[ad_1]
Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.
[ad_2]
Source link
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy.
